Biogen Stock Dips as Q4 Revenue Expected to Decline, But Full-Year Earnings Growth Forecast
-
Biogen's (BIIB) stock fell 0.65% compared to a 0.31% drop in the S&P 500 index. Over the past month, BIIB has lagged the Medical sector.
-
Biogen's upcoming Q4 2022 EPS is projected at $3.48, up 2.35% year-over-year. Revenue is expected to decrease 5.66% to $2.32 billion.
-
For full-year 2022, analysts estimate EPS of $15.48, representing 5.16% growth, and revenue of $9.47 billion, a 3.75% decline.
-
Biogen's stock has a Forward P/E ratio of 14.09 compared to an industry average of 24.18, indicating it trades at a discount. Its PEG ratio is 1.82 versus an industry average of 1.72.
-
The Medical - Biomedical and Genetics industry ranks in the top 33% of Zacks' 250+ industries, suggesting above-average growth prospects.